Product details
Background：Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
• Benralizumab for the treatment of asthma., PMID:29517082
• Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma., PMID:31734469
• Serum Concentration of IL-5 Receptor (IL-5R) and Associations with Disease Severity in Patients with Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD)., PMID:39062845
• A genetic effect of IL-5 receptor α polymorphism in patients with aspirin-exacerbated respiratory disease., PMID:23470716
• IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans., PMID:17620072
• Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output., PMID:19654410
• IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils., PMID:26276876
• Cord blood molecular biomarkers of eosinophilopoiesis: kinetic analysis of GATA-1, MBP1 and IL-5R alpha mRNA expression., PMID:20337967
